We are live on ! Find out more
BVXVW

BiondVax Pharmaceuticals Ltd.
BVXVW

Delisted

BVXVW was delisted on the 13th of May, 2020.

Back to rankings

3 hedge funds and large institutions have $32K invested in BiondVax Pharmaceuticals Ltd. in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

357% more capital invested

Capital invested by funds: $7K → $32K (+$25K)

50% more funds holding

Funds holding: 2 → 3 (+1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.1K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$80
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$27K +$29.1K +72,800 New
VIA
2
Vantage Investment Advisors
Pennsylvania
$4K – – –
UBS Group
3
UBS Group
Switzerland
$1K -$80 -199 -9%

BVXVW Hedge Fund Activity: Q4 2016 in Review

3 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in BiondVax Pharmaceuticals Ltd. (BVXVW) for Q4 2016, worth a combined $32K — up 357% from $7K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BVXVW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $29.1K. The largest seller was UBS Group, cutting an estimated $80.

  • 3 institutional investors held BiondVax Pharmaceuticals Ltd. (BVXVW) as of Q4 2016, up from 2 in Q3 2016.
  • Funds reported $32K of BiondVax Pharmaceuticals Ltd. stock for Q4 2016, up 357% quarter-over-quarter.
  • 1 fund opened new BiondVax Pharmaceuticals Ltd. positions in Q4 2016 and 0 closed out, a net change of +1 holder.
  • The largest BiondVax Pharmaceuticals Ltd. buyer in Q4 2016 was Susquehanna International Group, an estimated $29.1K added.
  • The largest BiondVax Pharmaceuticals Ltd. seller in Q4 2016 was UBS Group, an estimated $80 sold.

Based on aggregated 13F filings for Q4 2016.